GIA
NVAX icon

Gladstone Institutional Advisory’s Novavax NVAX Stock Holding History

Gladstone Institutional Advisory’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-2,405
Closed -$268K – 432
2020
Q4 		$268K Sell
2,405
-831
-26% -$88.3K 0.05% 241
2020
Q3 		$351K Buy
+3,236
New +$394K 0.08% 185

Other funds holding NVAX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Gladstone Institutional Advisory's NVAX Position: Q1 2021 in Review

Gladstone Institutional Advisory sold out of Novavax (NVAX) in Q1 2021, closing a stake of 2,405 shares — an estimated $268K sold.

Gladstone Institutional Advisory first reported a position in NVAX in Q3 2020 and held it in 2 quarters. The position peaked at $351K in Q3 2020. 389 funds tracked by Wall St. Rank hold NVAX as of Q1 2021.

  • Gladstone Institutional Advisory reported no remaining Novavax position as of Q1 2021 after selling out during the quarter.
  • Gladstone Institutional Advisory sold 2,405 Novavax shares in Q1 2021, an estimated $268K.
  • Gladstone Institutional Advisory first reported a position in Novavax in Q3 2020 and held it in 2 quarters.
  • Gladstone Institutional Advisory's Novavax position peaked at $351K in Q3 2020.
  • 389 funds tracked by Wall St. Rank held Novavax as of Q1 2021.

Based on Gladstone Institutional Advisory's 13F filing for Q1 2021, filed 17 May 2021.